Attributes | Values |
---|
rdf:type
| |
Description
| - Despite the fact that the statin treatment efficacy is very high, there are substantial differences in effects between treated individuals. It is supposed the genetic predisposition plays an important role in these differences but roles of individual polymorphisms are poorly understood. So far, as many as about thirty genes have been examined with ambiguous results. Apolipoprotein A5 is an important determinant of plasma lipid concentration and its genetic variation could account for some of the observed differences in the response to statin therapy. However, this has not been analyzed so far. We examined the putative association between APOA5 SNPs (T-1131C, Ser19Trp and Val153Met) and efficacy of three months of statin treatment in 188 Caucasians. Carriers of the APOA5 genotype TT-1131 benefited more from statin treatment in comparison to the C-1131 allele carriers ( LDL-C -36.3?15.1% vs. LDL-C -29.9?12.5%; P<0.005, Mann-Whitney test). Our results suggest that the APOA5 gene variations may play a
- Despite the fact that the statin treatment efficacy is very high, there are substantial differences in effects between treated individuals. It is supposed the genetic predisposition plays an important role in these differences but roles of individual polymorphisms are poorly understood. So far, as many as about thirty genes have been examined with ambiguous results. Apolipoprotein A5 is an important determinant of plasma lipid concentration and its genetic variation could account for some of the observed differences in the response to statin therapy. However, this has not been analyzed so far. We examined the putative association between APOA5 SNPs (T-1131C, Ser19Trp and Val153Met) and efficacy of three months of statin treatment in 188 Caucasians. Carriers of the APOA5 genotype TT-1131 benefited more from statin treatment in comparison to the C-1131 allele carriers ( LDL-C -36.3?15.1% vs. LDL-C -29.9?12.5%; P<0.005, Mann-Whitney test). Our results suggest that the APOA5 gene variations may play a (en)
|
Title
| - Impact of apolipoprotein A5 variants on statin treatment efficacy
- Impact of apolipoprotein A5 variants on statin treatment efficacy (en)
|
skos:prefLabel
| - Impact of apolipoprotein A5 variants on statin treatment efficacy
- Impact of apolipoprotein A5 variants on statin treatment efficacy (en)
|
skos:notation
| - RIV/00023001:_____/09:00001969!RIV10-MZ0-00023001
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00023001:_____/09:00001969
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - apolipoprotein A5; polymorphism; statin; cholesterol; efficacy (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Adámková, Věra
- Hubáček, Jaroslav
- Lánská, Věra
- Snejdrlova, M.
- Vrablik, M.
- Češka, R.
- Hirschfeldova, K.
- Prusiková, M.
|
http://linked.open...ain/vavai/riv/wos
| |
issn
| |
number of pages
| |